€14.1m loss for AGI
AGI Therapeutics has today reported audited financial results for the twelve months ended December 31 2007, inlcuding a net loss of €14.1m)
Other highlights included: Revenue of €392,000, cash and short term deposits at €30.9 m, R&D spend of €13.2m.
Loss per ordinary share was 20.9c for the period.
Commenting on the results, Dr John Devane, CEO of AGI, said: "Overall, 2007 was a busy year for AGI and we look forward to continued progress in 2008. Our focus this year will be to further advance our clinical programmes which will allow us achieve our commercial goals."
